Comparison of studies with recommendations regarding the expected/required LN yield following PLND for prostate cancer
Study | Study type | No. of cases | Type of PLND | Method of pathological assessment | Lymph nodes | ||
---|---|---|---|---|---|---|---|
Mean/median | Range | Recommended | |||||
Weingärtner et al31 | Cadaveric and clinical, single institution | 30 cadavers; 59 patients | Standard PLND | Palpable LNs submitted; xylene clearance used | Cadaver: 22.7/not given Patient: 20.5/not given | Cadaver: 8–56 Patient: 10–37 | 20 |
Barth et al29 | Clinical, single institution | 283 | Standard PLND | Palpable LNs submitted | Not given/16 | 5–40 | 13 |
Briganti et al18 | Clinical, single institution | 858 | ‘Most’ had extended PLND | Palpable LNs submitted | 15/14 | 2–40 | 28 |
Abdollah et al30 | Clinical, multi-institutional | 20 789 | Heterogeneous—not specified | Heterogeneous—not specified | 6.4/5 | 1–40 | 20 |
LN, lymph node; PLND, pelvic lymph node dissection.